Nvidia set to lose $180 billion in market value today as Meta weighs Google chips
NEW HAVEN - Arvinas, Inc. (NASDAQ:ARVN) announced that multiple abstracts on vepdegestrant will be presented at the San Antonio Breast Cancer Symposium taking place December 9-12, 2025 in Texas.
Vepdegestrant is an investigational PROTAC estrogen receptor degrader being developed with Pfizer (NYSE:PFE) for estrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Pfizer, with a market capitalization of $142.37 billion and rated as having "GREAT" financial health according to InvestingPro, appears undervalued based on Fair Value estimates. Investors seeking deeper insights can access comprehensive Pro Research Reports covering Pfizer and 1,400+ other top US equities through InvestingPro.
The presentations include subgroup analyses from the VERITAC-2 Phase 3 trial comparing vepdegestrant to fulvestrant, circulating tumor DNA biomarker analyses, real-world prevalence of ESR1 mutations, and data from the I-SPY2 Endocrine Optimization Pilot study evaluating vepdegestrant as monotherapy or in combination with other treatments.
Additionally, a trial-in-progress poster will present information on a Phase 1/2 trial evaluating vepdegestrant in combination with PF-07248144, a KAT6 inhibitor.
The U.S. Food and Drug Administration is currently reviewing the New Drug Application for vepdegestrant with a PDUFA action date of June 5, 2026. The FDA has granted Fast Track designation to the drug.
In September 2025, Arvinas and Pfizer announced plans to jointly select a third party for commercialization and potential further development of vepdegestrant.
The information is based on a press release statement from Arvinas, which is a clinical-stage biotechnology company focused on developing protein degradation therapies.
In other recent news, Pfizer Inc. has completed a significant $6 billion public notes offering, issuing notes with maturities ranging from 2027 to 2065. This offering was conducted under Pfizer’s shelf registration statement with the Securities and Exchange Commission. Additionally, Pfizer has finalized its $7 billion acquisition of Metsera, Inc., a Delaware-based company, as part of a merger agreement. Shareholders of Metsera received cash and potential additional payments based on milestone achievements. Following the acquisition, Pfizer plans to expand its obesity portfolio globally with a focus on oral medications, according to Chief Financial Officer Dave Denton. The company has approximately $5 billion available for further dealmaking over the next couple of years. Meanwhile, BioNTech confirmed that its collaboration with Pfizer remains strong, countering reports that suggested Pfizer might sell its stake.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.